TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Correction of Low Back Pain From Sacroiliac Malrotation With a Simple in Home Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 19 to 90~* Participants present with pain in their low back (below the waist) or their buttocks.~* Able to attend all 3 study visits at the participating physician's office.~* Able to attend at least the first two visits with someone willing to assist them in assessing their back and help them with the necessary exercise if need be.~* Willing to perform the corrective exercise and or wear the sacroiliac stabilization belt at home as needed~* Their posterior superior iliac spines (PSISs) are not level on initial examination.~* The long dorsal sacroiliac ligament below at least one of the (PSISs) is tender to palpation on initial examination.~Exclusion Criteria:~* Pain experienced is lumbar in origin~* Pain secondary to hip or other pathology~* PSISs are level at initial examination~* No tenderness to pressure under the PSISs~* Severe pain elsewhere in the body, making the assessment of back pain difficult.~* Presence of ankylosing spondylitis (seen on x-ray, pain worse at night, relieved by exercise, abnormal C reactive protein (CRP) or erythrocyte sedimentation rate (ESR)~* Obvious leg length discrepancy (\> 1 ½ cm) when measured umbilicus to medial malleolus.~* Location of PSISs cannot be assessed accurately due to back mice or obesity.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Immediate corrective exercises (Type: EXPERIMENTAL): At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that.
- Immediate use of pelvic support belt (Type: EXPERIMENTAL): Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that.
- Delayed treatment (Type: ACTIVE_COMPARATOR): These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.~The concurrent use of both treatments will be assessed at their last visit one month after that.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Two Toothpastes on Bacteria in Saliva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Personnel: GSKCH permanent and contract/contingency workers.~* Consent: Demonstrated understanding of the study and was willing to participate and had received a signed and dated copy of the informed consent form.~* Compliance: Understood, was willing and able and complied with all study procedures and restrictions.~* General Health: Good general health~* Oral Health: Good oral health~* Salivary Flow Rate: Had a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2milliliter per minute (ml/min); stimulated whole saliva flow rate ≥ 0.8ml/min)~Exclusion Criteria:~* Study personnel: Members of the clinical study staff.~* Pregnancy: Pregnant Women~* Breast-feeding: Women who were breast-feeding.~* Allergy/Intolerance: Had Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.~* Medication: a) Used an antimicrobial mouthwash within 48 hours of the test visit e.g. Listerine, Corsodyl etc. b) had taken, antibiotics within 2 weeks of the test visit.~* Oral Surgery and Dental Conditions: a)Had an on-going dental treatment b) Had any oral surgery or extraction within 6 weeks of screening c) Symptoms of oral pain or any self-reported oral ulcers or herpetic lesions~* Clinical Study Participation: a) Participation in a clinical study where they received an investigational drug within 2 weeks of the screening visit b) Previously participated in this study.~* Substance Abstinence: Participant who were unwilling to abstain from smoking for at least 2 hours prior to treatment visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Zinc-A toothpaste (Type: EXPERIMENTAL): In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
- Zinc-B toothpaste (Type: EXPERIMENTAL): In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
- Mineral Water (Type: OTHER): In this arm, participants received mineral water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants must have met all of the following criteria to be included in this study:~  1. Diagnosis of epilepsy~ 2. Initiated treatment with Fycompa at any time after 01 Jan 2014~ 3. Provided written informed consent by the participant or the participant's legally authorized representative signed for the use of medical records (if required by an Institutional Review Board \[IRB\] or Independent Ethics Committee \[IEC\], or by regulatory authorities).~Exclusion Criteria:~* Not applicable

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fycompa (Type: None): Participants diagnosed with epilepsy and treated with Fycompa

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peri- or postmenopausal women~* DSM-5 criteria for Insomnia disorder, with onset of symptoms attributed to hot flashes~* Some awakenings co-occur with a hot flash~* Score on the Insomnia Severity Index (ISI) measure ≥15~* Hot flashes present, including at night~Exclusion Criteria:~* Diagnosis of other primary sleep disorders~* Shift workers~* Current or expected use of hypnotic medications~* Current major depressive episode~* Lifetime history of bipolar disorder, psychosis, or other serious mental health problem~* Current alcohol/substance use disorder~* Obesity~* Renal or hepatic disease~* Pregnancy or breastfeeding~* Recent malignancy~* Recent surgery~* Neurological disorder or cardiovascular disease raising safety concerns~* Medical instability considered to interfere with study procedures~* Concomitant medications with drug interaction or co-administration concerns~* Contraindications or allergic responses to suvorexant~* Recent or planned travel across time zones~* Excessive coffee or cigarette use

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- suvorexant (Type: EXPERIMENTAL): suvorexant 10-20 mg taken at bedtime for four weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo taken at bedtime for four weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects were enrolled voluntarily and understood the contents of this clinical trial.~* Male or female Parkinson disease (PD) patients between 50 and 80 years~* Subjects who had not received prokinetics (itopride, mosapride, Corydalis tuber, levosulpiride, domperidone, etc.) at least 2 months prior to baseline visit~* Subjects complained at least one symptom of the following that suggests abnormal bowel functions: anorexia, nausea, abdominal distension, dyspepsia, early satiety, dysphagia, foreign body sensation associated with a meal, symptoms of gastroesophageal reflux, constipation, and defecation problem.~Exclusion Criteria:~* History of a gastrointestinal operation~* Subjects with active gastrointestinal diseases under treatment of gastroenterology within 1 month~* Existence of clinically significant cognitive decline or K-Minimental Status Exam score 20 or less~* Subjects had depression or other psychiatric disorders treated with medications such as antidepressants or antipsychotics; mood tranquilizers, benzodiazepines, and sleep pills were permitted with fixed dose during a period of the clinical trial~* Subjects with severe active comorbidities which could interfere the quality of life of the patient~* Subjects with medical conditions which make difficult to be enrolled to the trial judged by clinicians~* Subjects with hypersensitivity or adverse event related to DA-9701 (Motilitone)~* Prior participation to other clinical trials within 3 months

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Motilitone arm (Type: EXPERIMENTAL): DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
- Placebo arm (Type: PLACEBO_COMPARATOR): DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, aged ≥18.~* Normal healthy volunteers based on medical history, clinical assessments, and laboratory assessments.~* Body mass index 25-35 kg/m2.~* Willingness to maintain current activity level.~* Willingness to adhere to the Therapeutic Lifestyle Changes (TLC)diet during screening and treatment washout periods.~Exclusion Criteria:~* Intolerance to omega-3 fatty acids, ethyl esters, or fish.~* Unable or unwilling to eat the study meals.~* Use of fish oil, other EPA or DHA containing supplements, or EPA and/or DHA fortified foods within 60 days of Visit 2, or during the study.~* Consumption of any fish within 7 days of Visit 2, or during the study.~* Use of flaxseed, perilla seed, hemp, spirulina, or black currant oils within 7 days of Visit 2, or during the study.~* History of malabsorption syndrome, Crohn's disease, acute or chronic pancreatitis, pancreatic insufficiency, small bowel resection.~* Women who are pregnant, lactating, or planning to become pregnant during the study period, or women of childbearing potential who are not using acceptable contraceptive methods. A woman is considered of childbearing potential if she is not surgically sterile or is less than 1 year since last menstrual period. Examples of acceptable contraceptive methods include abstinence, intrauterine device (IUD) or double barrier method, oral or injectable contraceptives.~* Recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as \>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).~* Exposure to any investigational product, within 28 days prior to Visit 1.~* Any other condition the investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Epanova-Lovaza-Epanova-Lovaza (Type: ACTIVE_COMPARATOR): None
- Lovaza-Epanova-Lovaza-Epanova (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of Dr. Gonzalez~* ≥18 years of age~* Node-negative left breast cancer~* Invasive or DCIS breast cancer~* Prior lumpectomy~* Deemed appropriate for treatment in the prone position by the treating physician~* Able to tolerate prone position and breath hold during CT simulation~Exclusion Criteria:~* \<18 years of age~* Patients requiring treatment in supine position

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Verify radiation dose to heart and lung (Type: EXPERIMENTAL): Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.~* Biopsy confirmed active lupus nephritis.~* Clinically active lupus renal disease at screening requiring /receiving induction therapy with Standard of Care medications.~* Autoantibody-positive.~Key Exclusion Criteria:~* Pregnant or nursing.~* On dialysis within the past year.~* Treatment with belimumab within the past year .~* Receipt of induction therapy with cyclophosphamide within 3 months prior to induction therapy for the study.~* Receipt of any B cell targeted therapy (for example, rituximab), investigational biological agent within the past year.~* Severe active central nervous system (CNS) lupus.~* Required management of acute or chronic infections within the past 60 days.~* Current drug or alcohol abuse or dependence.~* Tested positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.~* History of severe allergic reaction to contrast agents or biological medicines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo plus standard therapy (Type: PLACEBO_COMPARATOR): Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
- Belimumab 10 mg/kg plus standard therapy (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- patients admitted at the emergency department with a diagnosis of severe sepsis or septic shock in whom amikacin is indicatied~Exclusion Criteria:~* \< 18 years~* pregnancy~* burns~* amikacin treatment in the previous 2 weeks~* known allergy to aminoglycosides~* Do Not Reanimate Code ≥ 2~* Hospitalized patients with a prolonged deep venous or arterial catheder~* Continuous renal replacement, intermittent hemodialysis and death within the time of start of amikacin replacement and 1 hour later

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amikacin standard dose (Type: ACTIVE_COMPARATOR): amikacin in a single standard dose
- amikacin dose for critical care patients (Type: ACTIVE_COMPARATOR): amikacin in a single dose for critical care patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patients with previously untreated WM and those who have received prior therapy are eligible~* Must have received prior therapy for their WM and have relapsed or refractory WM.~* CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment.~* Measurable disease~* ECOG Performance Status 0,1, or 2~* Total bilirubin \< 2.0 mg/dl~* AST \< 3 x ULN~* Life expectancy of greater than 12 weeks~Exclusion Criteria:~* Uncontrolled infection~* Other active malignancies~* Cytotoxic chemotherapy less than 3 weeks, or biologic therapy less than 2 weeks, or corticosteroids less than 2 weeks, prior to registration.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational~* Known to be HIV positive or HEP B positive~* Radiation therapy less than 2 weeks prior to registration~* Grade 2 or greater peripheral neuropathy~* Myocardial infarction within 6 months rior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~* Hypersensitivity to bortezomib, boron, or mannitol~* Pregnant or breast feeding women~* Other investigational drugs within 14 days of enrollment~* Serious medical or psychiatric illness likely to interfere with participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bortezomib and rituximab (Type: EXPERIMENTAL): bortezomib and rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants ages; Cohort 1: 12 years and older at the time of consent. Cohort 2: 2 years to under 12 years old at the time of consent.~* Has confrimed clinical diagnosis of active AD according to Hanifin and Rajka criteria and has at least 6 months history prior to screening and has been clinically stable for more than 1 month~* Has at least 1% and no more than 30% BSA at baseline/Day1, excluding scalp, genitals and groin area~* Has a Investigator's static global assessment (ISGA) score of Mild (2) or Moderate (3) on Day 1.~Exclusion Criteria:~* Has other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.~* Participants had previous treatment with any topical or systemic PDE-4 inhibitor.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Crisaborole ointment 2% once daily (QD) vs vehicle QD (Type: EXPERIMENTAL): intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
- Crisaborole ointment 2% twice daily (BID) vs vehicle BID (Type: EXPERIMENTAL): Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete